Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 4/20 | 0.42 |
| ▸ | SRC | P12931 | 8/20 | 0.39 |
| ▸ | ABL1 | P00519 | 3/20 | 0.39 |
| ▸ | HCK | P08631 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21337672 | 0.91 | PIK3CD (0.47) | RETSRCABL1HCKPIK3CD | |
| SCHEMBL16783414 | 0.84 | PIK3CD (0.44) | RETSRCABL1HCKPIK3CD | |
| SCHEMBL16783573 | 0.82 | KDM4E (0.41) | RETSRCABL1HCKPIK3CD | |
| SCHEMBL16783509 | 0.81 | PIK3CD (0.59) | SRCABL1HCKPIK3CDPIK3CA | |
| SCHEMBL16783387 | 0.81 | RET (0.44) | RETSRCABL1HCKPIK3CD | |
| SCHEMBL16806435 | 0.79 | PIK3CD (0.38) | RETSRCABL1PIK3CDPIK3CA | |
| SCHEMBL16843157 | 0.79 | PIK3CD (0.38) | RETPIK3CDPIK3CAPIK3CBPIK3CG | |
| Hydrochloric Acid SCHEMBL16783880 | 0.78 | PIK3CD (0.37) | RETSRCPIK3CDPIK3CAPIK3CB | |
| Hydrochloric Acid SCHEMBL16783538 | 0.78 | PIK3CD (0.37) | RETSRCPIK3CDPIK3CAPIK3CB | |
| SCHEMBL16783832 | 0.78 | PIK3CD (0.40) | RETSRCABL1HCKPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083617-B1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-09-11 | — | — | EP | disclosed |
| EP-3083617-B1 | ISOCHROMENE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-09-11 | — | — | EP | disclosed |
| US-9321776-B2 | Isochromene derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-04-26 | — | — | US | disclosed |
| US-9321776-B2 | Isochromene derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-04-26 | — | — | US | disclosed |
| US-9321776-B2 | Isochromene derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-04-26 | — | — | US | disclosed |
| US-20150166549-A1 | ISOCHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-18 | — | — | US | disclosed |
| US-20150166549-A1 | ISOCHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-18 | — | — | US | disclosed |
| US-20150166549-A1 | ISOCHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166549-A1 | ISOCHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | PIKFYVE, IP6K2, IP6K3 | RET 815/4885SRC 311/4885ABL1 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.